Jiang Lei, Xu Lingzhi, Xie Jiajun, Li Sisi, Guan Yanchun, Zhang Yan, Hou Zhijie, Guo Tao, Shu Xin, Wang Chang, Fan Wenjun, Si Yang, Yang Ya, Kang Zhijie, Fang Meiyun, Liu Quentin
a Institute of Cancer Stem Cell; Dalian Medical University; Dalian, China; State Key Laboratory of Oncology in South China; Cancer Center; Sun Yat-sen University ; Guangzhou , China.
Cancer Biol Ther. 2015;16(3):466-76. doi: 10.1080/15384047.2015.1016658.
Glucocorticoid (GC) resistance remains a major obstacle to successful treatment of lymphoid malignancies. Till now, the precise mechanism of GC resistance remains unclear. In the present study, dexamethasone (Dex) inhibited cell proliferation, arrested cell cycle in G0/G1-phase, and induced apoptosis in Dex-sensitive acute lymphoblastic leukemia cells. However, Dex failed to cause cell death in Dex-resistant lymphoid malignant cells. Intriguingly, we found that autophagy was induced by Dex in resistant cells, as indicated by autophagosomes formation, LC3-I to LC3-II conversion, p62 degradation, and formation of acidic autophagic vacuoles. Moreover, the results showed that Dex reduced the activity of mTOR pathway, as determined by decreased phosphorylation levels of mTOR, Akt, P70S6K and 4E-BP1 in resistant cells. Inhibition of autophagy by either chloroquine (CQ) or 3-methyladenine (3-MA) overcame Dex-resistance in lymphoid malignant cells by increasing apoptotic cell death in vitro. Consistently, inhibition of autophagy by stably knockdown of Beclin1 sensitized Dex-resistant lymphoid malignant cells to induction of apoptosis in vivo. Thus, inhibition of autophagy has the potential to improve lymphoid malignancy treatment by overcoming GC resistance.
糖皮质激素(GC)抵抗仍然是成功治疗淋巴系统恶性肿瘤的主要障碍。到目前为止,GC抵抗的确切机制仍不清楚。在本研究中,地塞米松(Dex)抑制了Dex敏感的急性淋巴细胞白血病细胞的增殖,使细胞周期停滞在G0/G1期,并诱导其凋亡。然而,Dex未能导致Dex耐药的淋巴系统恶性细胞死亡。有趣的是,我们发现Dex在耐药细胞中诱导了自噬,这表现为自噬体形成、LC3-I向LC3-II的转化、p62降解以及酸性自噬泡的形成。此外,结果显示Dex降低了mTOR通路的活性,这是通过耐药细胞中mTOR、Akt、P70S6K和4E-BP1磷酸化水平的降低来确定的。在体外,通过氯喹(CQ)或3-甲基腺嘌呤(3-MA)抑制自噬,可通过增加凋亡细胞死亡来克服淋巴系统恶性细胞中的Dex耐药性。同样,通过稳定敲低Beclin1抑制自噬,可使Dex耐药的淋巴系统恶性细胞在体内对凋亡诱导敏感。因此,抑制自噬有可能通过克服GC抵抗来改善淋巴系统恶性肿瘤的治疗。